Global Central Nervous System (CNS) Therapeutic Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

A central nervous system (CNS) disease can affect either the brain or the spinal cord which leads to neurological or psychiatric disorders.

Report Overview

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Central Nervous System (CNS) Therapeutic estimated at US$ 76830 million in the year 2022, is projected to reach a revised size of US$ 93600 million by 2028, growing at a CAGR of 3.3% during the forecast period 2022-2028.

Advancements in diagnostics, therapeutics and drug discovery techniques will further trigger the growth of central nervous system therapeutic market.

Report Scope

This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Central Nervous System (CNS) Therapeutic companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Central Nervous System (CNS) Therapeutic market. Further, it explains the major drivers and regional dynamics of the global Central Nervous System (CNS) Therapeutic market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

Pfizer

Biogen

Johnson & Johnson

Eli Lilly

Otsuka America Pharmaceutical

Merck

Astrazeneca

Novartis

Teva Pharmaceutical Industries

Takeda

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.

Neurovascular

Trauma

Mental Health

Degenerative Disorder

Infections

Cancer

Clinical Application

Others

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Central Nervous System (CNS) Therapeutic market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Central Nervous System (CNS) Therapeutic market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Central Nervous System (CNS) Therapeutic, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Central Nervous System (CNS) Therapeutic, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Central Nervous System (CNS) Therapeutic revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Central Nervous System (CNS) Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Central Nervous System (CNS) Therapeutic revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Pfizer, Biogen, Johnson & Johnson, Eli Lilly, Otsuka America Pharmaceutical, Merck, Astrazeneca, Novartis and Teva Pharmaceutical Industries, etc.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Central Nervous System (CNS) Therapeutic Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 Neurovascular

1.2.3 Trauma

1.2.4 Mental Health

1.2.5 Degenerative Disorder

1.2.6 Infections

1.2.7 Cancer

1.3 Market by Application

1.3.1 Global Central Nervous System (CNS) Therapeutic Market Growth Rate by Application: 2017 VS 2021 VS 2028

1.3.2 Clinical Application

1.3.3 Others

1.4 Study Objectives

1.5 Years Considered

2.1 Global Central Nervous System (CNS) Therapeutic Market Size (2017-2028)

2.2 Central Nervous System (CNS) Therapeutic Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028

2.3 Global Central Nervous System (CNS) Therapeutic Market Size by Region (2017-2022)

2.4 Global Central Nervous System (CNS) Therapeutic Market Size Forecast by Region (2023-2028)

2.5 Global Top Central Nervous System (CNS) Therapeutic Countries Ranking by Market Size

3.1 Global Central Nervous System (CNS) Therapeutic Revenue by Players

3.1.1 Global Central Nervous System (CNS) Therapeutic Revenue by Players (2017-2022)

3.1.2 Global Central Nervous System (CNS) Therapeutic Market Share by Players (2017-2022)

3.2 Global Central Nervous System (CNS) Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Company Covered: Ranking by Central Nervous System (CNS) Therapeutic Revenue

3.4 Global Central Nervous System (CNS) Therapeutic Market Concentration Ratio

3.4.1 Global Central Nervous System (CNS) Therapeutic Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Central Nervous System (CNS) Therapeutic Revenue in 2021

3.5 Global Central Nervous System (CNS) Therapeutic Key Players Head office and Area Served

3.6 Key Players Central Nervous System (CNS) Therapeutic Product Solution and Service

3.7 Date of Enter into Central Nervous System (CNS) Therapeutic Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Central Nervous System (CNS) Therapeutic Historic Revenue by Type (2017-2022)

4.2 Global Central Nervous System (CNS) Therapeutic Forecasted Revenue by Type (2023-2028)

5.1 Global Central Nervous System (CNS) Therapeutic Historic Market Size by Application (2017-2022)

5.2 Global Central Nervous System (CNS) Therapeutic Forecasted Market Size by Application (2023-2028)

6.1 North America Central Nervous System (CNS) Therapeutic Revenue by Company (2020-2022)

6.2 North America Central Nervous System (CNS) Therapeutic Revenue by Type (2017-2028)

6.3 North America Central Nervous System (CNS) Therapeutic Revenue by Application (2017-2028)

6.4 North America Central Nervous System (CNS) Therapeutic Revenue by Country (2017-2028)

6.4.1 U.S.

6.4.2 Canada

7.1 Europe Central Nervous System (CNS) Therapeutic Revenue by Company (2020-2022)

7.2 Europe Central Nervous System (CNS) Therapeutic Revenue by Type (2017-2028)

7.3 Europe Central Nervous System (CNS) Therapeutic Revenue by Application (2017-2028)

7.4 Europe Central Nervous System (CNS) Therapeutic Revenue by Country (2017-2028)

7.4.1 Germany

7.4.2 France

7.4.3 U.K.

7.4.4 Italy

7.4.5 Russia

8.1 Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Company (2020-2022)

8.2 Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Type (2017-2028)

8.3 Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Application (2017-2028)

8.4 Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Region (2017-2028)

8.4.1 China

8.4.2 Japan

8.4.3 South Korea

8.4.4 India

8.4.5 Australia

8.4.6 Taiwan

8.4.7 Indonesia

8.4.8 Thailand

8.4.9 Malaysia

8.4.10 Philippines

8.4.11 Vietnam

9.1 Latin America Central Nervous System (CNS) Therapeutic Revenue by Company (2020-2022)

9.2 Latin America Central Nervous System (CNS) Therapeutic Revenue by Type (2017-2028)

9.3 Latin America Central Nervous System (CNS) Therapeutic Revenue by Application (2017-2028)

9.4 Latin America Central Nervous System (CNS) Therapeutic Revenue by Country (2017-2028)

9.4.1 Mexico

9.4.2 Brazil

9.4.3 Argentina

10.1 Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Company (2020-2022)

10.2 Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Type (2017-2028)

10.3 Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Application (2017-2028)

10.4 Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Country (2017-2028)

10.4.1 Turkey

10.4.2 Saudi Arabia

10.4.3 U.A.E

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Central Nervous System (CNS) Therapeutic Products and Services

11.1.4 Pfizer Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022)

11.1.5 Pfizer Central Nervous System (CNS) Therapeutic SWOT Analysis

11.1.6 Pfizer Recent Developments

11.2 Biogen

11.2.1 Biogen Company Details

11.2.2 Biogen Business Overview

11.2.3 Biogen Central Nervous System (CNS) Therapeutic Products and Services

11.2.4 Biogen Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022)

11.2.5 Biogen Central Nervous System (CNS) Therapeutic SWOT Analysis

11.2.6 Biogen Recent Developments

11.3 Johnson & Johnson

11.3.1 Johnson & Johnson Company Details

11.3.2 Johnson & Johnson Business Overview

11.3.3 Johnson & Johnson Central Nervous System (CNS) Therapeutic Products and Services

11.3.4 Johnson & Johnson Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022)

11.3.5 Johnson & Johnson Central Nervous System (CNS) Therapeutic SWOT Analysis

11.3.6 Johnson & Johnson Recent Developments

11.4 Eli Lilly

11.4.1 Eli Lilly Company Details

11.4.2 Eli Lilly Business Overview

11.4.3 Eli Lilly Central Nervous System (CNS) Therapeutic Products and Services

11.4.4 Eli Lilly Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022)

11.4.5 Eli Lilly Central Nervous System (CNS) Therapeutic SWOT Analysis

11.4.6 Eli Lilly Recent Developments

11.5 Otsuka America Pharmaceutical

11.5.1 Otsuka America Pharmaceutical Company Details

11.5.2 Otsuka America Pharmaceutical Business Overview

11.5.3 Otsuka America Pharmaceutical Central Nervous System (CNS) Therapeutic Products and Services

11.5.4 Otsuka America Pharmaceutical Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022)

11.5.5 Otsuka America Pharmaceutical Central Nervous System (CNS) Therapeutic SWOT Analysis

11.5.6 Otsuka America Pharmaceutical Recent Developments

11.6 Merck

11.6.1 Merck Company Details

11.6.2 Merck Business Overview

11.6.3 Merck Central Nervous System (CNS) Therapeutic Products and Services

11.6.4 Merck Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022)

11.6.5 Merck Central Nervous System (CNS) Therapeutic SWOT Analysis

11.6.6 Merck Recent Developments

11.7 Astrazeneca

11.7.1 Astrazeneca Company Details

11.7.2 Astrazeneca Business Overview

11.7.3 Astrazeneca Central Nervous System (CNS) Therapeutic Products and Services

11.7.4 Astrazeneca Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022)

11.7.5 Astrazeneca Central Nervous System (CNS) Therapeutic SWOT Analysis

11.7.6 Astrazeneca Recent Developments

11.8 Novartis

11.8.1 Novartis Company Details

11.8.2 Novartis Business Overview

11.8.3 Novartis Central Nervous System (CNS) Therapeutic Products and Services

11.8.4 Novartis Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022)

11.8.5 Novartis Central Nervous System (CNS) Therapeutic SWOT Analysis

11.8.6 Novartis Recent Developments

11.9 Teva Pharmaceutical Industries

11.9.1 Teva Pharmaceutical Industries Company Details

11.9.2 Teva Pharmaceutical Industries Business Overview

11.9.3 Teva Pharmaceutical Industries Central Nervous System (CNS) Therapeutic Products and Services

11.9.4 Teva Pharmaceutical Industries Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022)

11.9.5 Teva Pharmaceutical Industries Central Nervous System (CNS) Therapeutic SWOT Analysis

11.9.6 Teva Pharmaceutical Industries Recent Developments

11.10 Takeda

11.10.1 Takeda Company Details

11.10.2 Takeda Business Overview

11.10.3 Takeda Central Nervous System (CNS) Therapeutic Products and Services

11.10.4 Takeda Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022)

11.10.5 Takeda Central Nervous System (CNS) Therapeutic SWOT Analysis

11.10.6 Takeda Recent Developments

12.1 Central Nervous System (CNS) Therapeutic Market Trends

12.2 Central Nervous System (CNS) Therapeutic Market Drivers

12.3 Central Nervous System (CNS) Therapeutic Market Challenges

12.4 Central Nervous System (CNS) Therapeutic Market Restraints

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.2 Data Source

14.2 Author Details

List of Tables

    Table 1. Global Central Nervous System (CNS) Therapeutic Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028

    Table 2. Key Players of Neurovascular

    Table 3. Key Players of Trauma

    Table 4. Key Players of Mental Health

    Table 5. Key Players of Degenerative Disorder

    Table 6. Key Players of Infections

    Table 7. Key Players of Cancer

    Table 8. Global Central Nervous System (CNS) Therapeutic Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028

    Table 9. Global Central Nervous System (CNS) Therapeutic Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028

    Table 10. Global Central Nervous System (CNS) Therapeutic Revenue by Region (2017-2022) & (US$ Million)

    Table 11. Global Central Nervous System (CNS) Therapeutic Revenue Market Share by Region (2017-2022)

    Table 12. Global Central Nervous System (CNS) Therapeutic Revenue by Players (2017-2022) & (US$ Million)

    Table 13. Global Central Nervous System (CNS) Therapeutic Market Share by Players (2017-2022)

    Table 14. Global Top Central Nervous System (CNS) Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System (CNS) Therapeutic as of 2021)

    Table 15. Ranking of Global Top Central Nervous System (CNS) Therapeutic Companies by Revenue (US$ Million) in 2021

    Table 16. Global 5 Largest Players Market Share by Central Nervous System (CNS) Therapeutic Revenue (CR5 and HHI) & (2017-2022)

    Table 17. Key Players Headquarters and Area Served

    Table 18. Key Players Central Nervous System (CNS) Therapeutic Product Solution and Service

    Table 19. Date of Key Manufacturers Enter into Central Nervous System (CNS) Therapeutic Market

    Table 20. Mergers & Acquisitions, Expansion Plans

    Table 21. Global Central Nervous System (CNS) Therapeutic Market Size by Type (2017-2022) & (US$ Million)

    Table 22. Global Central Nervous System (CNS) Therapeutic Revenue Market Share by Type (2017-2022)

    Table 23. Global Central Nervous System (CNS) Therapeutic Forecasted Market Size by Type (2023-2028) & (US$ Million)

    Table 24. Global Central Nervous System (CNS) Therapeutic Revenue Market Share by Type (2023-2028)

    Table 25. Global Central Nervous System (CNS) Therapeutic Market Size by Application (2017-2022) & (US$ Million)

    Table 26. Global Central Nervous System (CNS) Therapeutic Revenue Market Share by Application (2017-2022)

    Table 27. Global Central Nervous System (CNS) Therapeutic Forecasted Market Size by Application (2023-2028) & (US$ Million)

    Table 28. Global Central Nervous System (CNS) Therapeutic Revenue Market Share by Application (2023-2028)

    Table 29. North America Central Nervous System (CNS) Therapeutic Revenue by Company (2020-2022) & (US$ Million)

    Table 30. North America Central Nervous System (CNS) Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 31. North America Central Nervous System (CNS) Therapeutic Revenue by Type (2023-2028) & (US$ Million)

    Table 32. North America Central Nervous System (CNS) Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 33. North America Central Nervous System (CNS) Therapeutic Revenue by Application (2023-2028) & (US$ Million)

    Table 34. North America Central Nervous System (CNS) Therapeutic Revenue by Country (2017-2022) & (US$ Million)

    Table 35. North America Central Nervous System (CNS) Therapeutic Revenue by Country (2023-2028) & (US$ Million)

    Table 36. Europe Central Nervous System (CNS) Therapeutic Revenue by Company (2020-2022) & (US$ Million)

    Table 37. Europe Central Nervous System (CNS) Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 38. Europe Central Nervous System (CNS) Therapeutic Revenue by Type (2023-2028) & (US$ Million)

    Table 39. Europe Central Nervous System (CNS) Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 40. Europe Central Nervous System (CNS) Therapeutic Revenue by Application (2023-2028) & (US$ Million)

    Table 41. Europe Central Nervous System (CNS) Therapeutic Revenue by Country (2017-2022) & (US$ Million)

    Table 42. Europe Central Nervous System (CNS) Therapeutic Revenue by Country (2023-2028) & (US$ Million)

    Table 43. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Company (2020-2022) & (US$ Million)

    Table 44. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 45. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Type (2023-2028) & (US$ Million)

    Table 46. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 47. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Application (2023-2028) & (US$ Million)

    Table 48. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Region (2017-2022) & (US$ Million)

    Table 49. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue by Region (2023-2028) & (US$ Million)

    Table 50. Latin America Central Nervous System (CNS) Therapeutic Revenue by Company (2020-2022) & (US$ Million)

    Table 51. Latin America Central Nervous System (CNS) Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 52. Latin America Central Nervous System (CNS) Therapeutic Revenue by Type (2023-2028) & (US$ Million)

    Table 53. Latin America Central Nervous System (CNS) Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 54. Latin America Central Nervous System (CNS) Therapeutic Revenue by Application (2023-2028) & (US$ Million)

    Table 55. Latin America Central Nervous System (CNS) Therapeutic Revenue by Country (2017-2022) & (US$ Million)

    Table 56. Latin America Central Nervous System (CNS) Therapeutic Revenue by Country (2023-2028) & (US$ Million)

    Table 57. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Company (2020-2022) & (US$ Million)

    Table 58. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 59. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Type (2023-2028) & (US$ Million)

    Table 60. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 61. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Application (2023-2028) & (US$ Million)

    Table 62. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Country (2017-2022) & (US$ Million)

    Table 63. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue by Country (2023-2028) & (US$ Million)

    Table 64. Pfizer Company Details

    Table 65. Pfizer Business Overview

    Table 66. Pfizer Central Nervous System (CNS) Therapeutic Product and Services

    Table 67. Pfizer Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022) & (US$ Million)

    Table 68. Pfizer Central Nervous System (CNS) Therapeutic SWOT Analysis

    Table 69. Pfizer Recent Developments

    Table 70. Biogen Company Details

    Table 71. Biogen Business Overview

    Table 72. Biogen Central Nervous System (CNS) Therapeutic Product and Services

    Table 73. Biogen Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022) & (US$ Million)

    Table 74. Biogen Central Nervous System (CNS) Therapeutic SWOT Analysis

    Table 75. Biogen Recent Developments

    Table 76. Johnson & Johnson Company Details

    Table 77. Johnson & Johnson Business Overview

    Table 78. Johnson & Johnson Central Nervous System (CNS) Therapeutic Product and Services

    Table 79. Johnson & Johnson Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022) & (US$ Million)

    Table 80. Johnson & Johnson Central Nervous System (CNS) Therapeutic SWOT Analysis

    Table 81. Johnson & Johnson Recent Developments

    Table 82. Eli Lilly Company Details

    Table 83. Eli Lilly Business Overview

    Table 84. Eli Lilly Central Nervous System (CNS) Therapeutic Product and Services

    Table 85. Eli Lilly Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022) & (US$ Million)

    Table 86. Eli Lilly Central Nervous System (CNS) Therapeutic SWOT Analysis

    Table 87. Eli Lilly Recent Developments

    Table 88. Otsuka America Pharmaceutical Company Details

    Table 89. Otsuka America Pharmaceutical Business Overview

    Table 90. Otsuka America Pharmaceutical Central Nervous System (CNS) Therapeutic Product and Services

    Table 91. Otsuka America Pharmaceutical Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022) & (US$ Million)

    Table 92. Otsuka America Pharmaceutical Central Nervous System (CNS) Therapeutic SWOT Analysis

    Table 93. Otsuka America Pharmaceutical Recent Developments

    Table 94. Merck Company Details

    Table 95. Merck Business Overview

    Table 96. Merck Central Nervous System (CNS) Therapeutic Product and Services

    Table 97. Merck Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022) & (US$ Million)

    Table 98. Merck Central Nervous System (CNS) Therapeutic SWOT Analysis

    Table 99. Merck Recent Developments

    Table 100. Astrazeneca Company Details

    Table 101. Astrazeneca Business Overview

    Table 102. Astrazeneca Central Nervous System (CNS) Therapeutic Product and Services

    Table 103. Astrazeneca Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022) & (US$ Million)

    Table 104. Astrazeneca Central Nervous System (CNS) Therapeutic SWOT Analysis

    Table 105. Astrazeneca Recent Developments

    Table 106. Novartis Company Details

    Table 107. Novartis Business Overview

    Table 108. Novartis Central Nervous System (CNS) Therapeutic Product and Services

    Table 109. Novartis Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022) & (US$ Million)

    Table 110. Novartis Central Nervous System (CNS) Therapeutic SWOT Analysis

    Table 111. Novartis Recent Developments

    Table 112. Teva Pharmaceutical Industries Company Details

    Table 113. Teva Pharmaceutical Industries Business Overview

    Table 114. Teva Pharmaceutical Industries Central Nervous System (CNS) Therapeutic Product and Services

    Table 115. Teva Pharmaceutical Industries Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022) & (US$ Million)

    Table 116. Teva Pharmaceutical Industries Central Nervous System (CNS) Therapeutic SWOT Analysis

    Table 117. Teva Pharmaceutical Industries Recent Developments

    Table 118. Takeda Company Details

    Table 119. Takeda Business Overview

    Table 120. Takeda Central Nervous System (CNS) Therapeutic Product and Services

    Table 121. Takeda Central Nervous System (CNS) Therapeutic Revenue in Central Nervous System (CNS) Therapeutic Business (2017-2022) & (US$ Million)

    Table 122. Takeda Central Nervous System (CNS) Therapeutic SWOT Analysis

    Table 123. Takeda Recent Developments

    Table 124. Central Nervous System (CNS) Therapeutic Market Trends

    Table 125. Central Nervous System (CNS) Therapeutic Market Drivers

    Table 126. Central Nervous System (CNS) Therapeutic Market Challenges

    Table 127. Central Nervous System (CNS) Therapeutic Market Restraints

    Table 128. Research Programs/Design for This Report

    Table 129. Key Data Information from Secondary Sources

    Table 130. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Central Nervous System (CNS) Therapeutic Sales Market Share by Type: 2021 VS 2028

    Figure 2. Neurovascular Features

    Figure 3. Trauma Features

    Figure 4. Mental Health Features

    Figure 5. Degenerative Disorder Features

    Figure 6. Infections Features

    Figure 7. Cancer Features

    Figure 8. Global Central Nervous System (CNS) Therapeutic Sales Market Share by Application: 2021 VS 2028

    Figure 9. Clinical Application Case Studies

    Figure 10. Others Case Studies

    Figure 11. Central Nervous System (CNS) Therapeutic Report Years Considered

    Figure 12. Global Central Nervous System (CNS) Therapeutic Revenue, (US$ Million), 2017 VS 2021 VS 2028

    Figure 13. Global Central Nervous System (CNS) Therapeutic Market Size 2017-2028 (US$ Million)

    Figure 14. Global Central Nervous System (CNS) Therapeutic Market Size Market Share by Region: 2021 VS 2028

    Figure 15. Global Central Nervous System (CNS) Therapeutic Revenue Market Share by Region in 2017 VS 2022

    Figure 16. Global Top 10 Central Nervous System (CNS) Therapeutic Countries Ranking by Market Size (US$ Million) in 2021

    Figure 17. Global Central Nervous System (CNS) Therapeutic Market Share by Players in 2021

    Figure 18. Global Top Central Nervous System (CNS) Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System (CNS) Therapeutic as of 2021)

    Figure 19. The Top 10 and 5 Players Market Share by Central Nervous System (CNS) Therapeutic Revenue in 2021

    Figure 20. North America Central Nervous System (CNS) Therapeutic Revenue Market Share by Company in 2021

    Figure 21. North America Central Nervous System (CNS) Therapeutic Revenue Market Share by Type (2017-2028)

    Figure 22. North America Central Nervous System (CNS) Therapeutic Revenue Market Share by Application (2017-2028)

    Figure 23. North America Central Nervous System (CNS) Therapeutic Revenue Share by Country (2017-2028)

    Figure 24. U.S. Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 25. Canada Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 26. Europe Central Nervous System (CNS) Therapeutic Revenue Market Share by Company in 2021

    Figure 27. Europe Central Nervous System (CNS) Therapeutic Revenue Market Share by Type (2017-2028)

    Figure 28. Europe Central Nervous System (CNS) Therapeutic Revenue Market Share by Application (2017-2028)

    Figure 29. Europe Central Nervous System (CNS) Therapeutic Revenue Share by Country (2017-2028)

    Figure 30. Germany Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 31. France Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 32. U.K. Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 33. Italy Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 34. Russia Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 35. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue Market Share by Company in 2021

    Figure 36. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue Market Share by Type (2017-2028)

    Figure 37. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue Market Share by Application (2017-2028)

    Figure 38. Asia Pacific Central Nervous System (CNS) Therapeutic Revenue Share by Region (2017-2028)

    Figure 39. China Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 40. Japan Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 41. South Korea Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 42. India Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 43. Australia Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 44. Taiwan Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 45. Indonesia Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 46. Thailand Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 47. Malaysia Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 48. Philippines Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 49. Vietnam Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 50. Latin America Central Nervous System (CNS) Therapeutic Revenue Market Share by Company in 2021

    Figure 51. Latin America Central Nervous System (CNS) Therapeutic Revenue Market Share by Type (2017-2028)

    Figure 52. Latin America Central Nervous System (CNS) Therapeutic Revenue Market Share by Application (2017-2028)

    Figure 53. Latin America Central Nervous System (CNS) Therapeutic Revenue Share by Country (2017-2028)

    Figure 54. Mexico Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 55. Brazil Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 56. Argentina Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 57. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue Market Share by Company in 2021

    Figure 58. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue Market Share by Type (2017-2028)

    Figure 59. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue Market Share by Application (2017-2028)

    Figure 60. Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue Share by Country (2017-2028)

    Figure 61. Turkey Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 62. Saudi Arabia Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 63. U.A.E Central Nervous System (CNS) Therapeutic Revenue (2017-2028) & (US$ Million)

    Figure 64. Pfizer Revenue Growth Rate in Central Nervous System (CNS) Therapeutic Business (2017-2022)

    Figure 65. Biogen Revenue Growth Rate in Central Nervous System (CNS) Therapeutic Business (2017-2022)

    Figure 66. Johnson & Johnson Revenue Growth Rate in Central Nervous System (CNS) Therapeutic Business (2017-2022)

    Figure 67. Eli Lilly Revenue Growth Rate in Central Nervous System (CNS) Therapeutic Business (2017-2022)

    Figure 68. Otsuka America Pharmaceutical Revenue Growth Rate in Central Nervous System (CNS) Therapeutic Business (2017-2022)

    Figure 69. Merck Revenue Growth Rate in Central Nervous System (CNS) Therapeutic Business (2017-2022)

    Figure 70. Astrazeneca Revenue Growth Rate in Central Nervous System (CNS) Therapeutic Business (2017-2022)

    Figure 71. Novartis Revenue Growth Rate in Central Nervous System (CNS) Therapeutic Business (2017-2022)

    Figure 72. Teva Pharmaceutical Industries Revenue Growth Rate in Central Nervous System (CNS) Therapeutic Business (2017-2022)

    Figure 73. Takeda Revenue Growth Rate in Central Nervous System (CNS) Therapeutic Business (2017-2022)

    Figure 74. Bottom-up and Top-down Approaches for This Report

    Figure 75. Data Triangulation

    Figure 76. Key Executives Interviewed